Phase I open label study to evaluate the safety and immunogenicity of heat-labile toxin (LT) vaccination [Escherichia coli vaccine] by transcutaneous immunisation (TCI) in the elderly and compare elderly immune responses with those developed by healthy adults
Phase of Trial: Phase I
Latest Information Update: 11 Dec 2017
At a glance
- Drugs Heat-labile enterotoxin E coli (Primary)
- Indications Enterotoxigenic Escherichia coli infections
- Focus Adverse reactions
- Sponsors Intercell USA; Valneva USA
- 11 Dec 2017 According to a Valneva media release, Intercell USA changed its name to Valneva USA.
- 05 Jun 2008 New trial record.